Before Pfizer buyout, Hospira links with Pfenex for Lucentis biosimilar
This article was originally published in Scrip
Executive Summary
Hospira and Pfenex have agreed to co-develop PF582, a biosimilar for Lucentis (ranibizumab) – a blockbuster treatment for wet age-related macular degeneration (AMD) and other ophthalmic indications – less than a week after Pfizer said it would buy Hospira for $17bn.